Residual cancer burden index

From Libre Pathology
Revision as of 23:57, 15 October 2024 by Michael (talk | contribs)
Jump to navigation Jump to search

Residual cancer burden index, abbreviated RCB, is an empirical predictor of outcome in breast cancer in the post-neoadjuvant therapy setting.[1]

Definition

The RCB index is defined as:[2]

Where:

The inputs to are:

Interpretation

The original paper stratified patients into three groups using two cut-points:[2]

  • Low risk (RCB-I): RCB > 0 and < 1.36.
  • Intermediate risk (RCB-II): RCB > 1.36 and < 3.28.
  • High risk (RCB-III): RCB > 3.28.

If one includes the group without any residual disease: there are four groups (RCB-0, RCB-I, RCB-II, RCB-III).

See also

References

  1. Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JM, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF (January 2022). "Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients". Lancet Oncol 23 (1): 149–160. doi:10.1016/S1470-2045(21)00589-1. PMID 34902335.
  2. 2.0 2.1 Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L (October 2007). "Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy". J Clin Oncol 25 (28): 4414–22. doi:10.1200/JCO.2007.10.6823. PMID 17785706.

External links